|
Studieprotocollen non Hodgkin lymfoom (NHL)
Nieuw gediagnosticeerd
Diagnose
- MRI studie (gesloten per 2 januari 2012)
Folliculair non Hodgkin lymfoom
- HOVON 73/PRIMA studie : A multicentre, phase III, open-label, randomized study in patients with advanced follicular lymphoma evaluating the benefit of maintenance therapy with Rituximab (MabThera®) after induction of response with chemotherapy plus Rituximab in comparison with no maintenance therapy: (gesloten)
- TAMIL studie Treatment induced alterations in microenvironment in follicular lymphoma.
A multi-center descriptive study (open)
Mantelcel lymfoom < 66 jaar
- HOVON75 MCL: Bortezomib maintenance therapy in newly diagnosed patients with mantle cell lymphoma, responsive on rituximab combined with CHOP and high dose Ara-C and after BEAM with auto PSCT rescue. (gesloten per 1 maart 2012)
Mantelcel lymfoom >66 jaar
- HOVON 55 MCL: Efficacy of maintenance therapy with rituximab after induction chemotherapy (R-CHOP vs. R-FC) for elderly patients with mantle cell lymphoma not suitable for autologous stem cell transplantation (Gesloten per 22 okt 2010)
MALT lymfoom
- Tranamalt versie 4.0 A phase II study of oral fludarabine in t(11;18) positive gastric MALT lymphoma, advanced gastric MALT lymphoma and nongastric MALT lymphoma. Voor dit protocol dienen patiënten verwezen te worden naar het NKI, studiecoördinator dr JP de Boer
Grootcellig B cel non Hodgkin lymfoom
- HOVON 63 NHL: Randomized phase III study of Rituximab with intensified CHOP chemotherapy (R-iCHOP-14) versus Rituximab with High-Dose Sequential Therapy and Autologous Stem Cell Transplantation (R-HDT+ASCT) in Adult Patients (18-65 yrs) with Stage II-IV High-intermediate or High Risk Diffuse Large B-Cell Lymphoma (gesloten)
- HOVON 77 NHL: Efficacy and safety of a single dose of 14.8 MBq/kg (0.4 mCi/kg) 90Y-ibritumomab tiuxetan ("Zevalin") in elderly patients with diffuse large B-cell lymphoma and FDG-PET positive partial remission following first-line R-CHOP therapy. A Phase II clinical trial (gesloten)
- HOVON 84 NHL: Randomized phase III study on the effect of early intensification of rituximab in combination with 2-weekly CHOP chemotherapy followed by rituximab maintenance in patients with diffuse large B-cell lymphoma (open)
T cel non Hodgkin lymfoom
- HOVON 69: A phase II study of anti-CD52 monoclonal antibody (Alemtuzumab, MabCampath®) with 2-weekly CHOP chemotherapy (Camp-CHOP 14) in patients with mature T-cell non-Hodgkin’s lymphoma (gesloten)
- HOVON 90: ACT-1. Campath-1H (Alemtuzumab) in combination with 2- weekly CHOP versus 2-weekly CHOP alone and consolidated by autologous stem cell transplant, in young patients with previously untreated systemic peripheral Tcell lymphomas (open)
- HOVON 91: ACT-2. Campath-1H (Alemtuzumab) given in combination with 2-weekly CHOP versus 2-weekly CHOP alone in elderly patients with previously untreated systemic peripheral T-cell lymphomas 61-80 yr (open)
Lymfoom in CNS
- HOVON 105: Rituximab in Primary Central Nervous system Lymphoma. A randomized HOVON/ALLG intergroup study.
Voor dit protocol dienen patienten doorverwezen te worden naar NKI.
- Protocol en achtergronden
- Patienteninformatie
- Logistiek studie AMC
Recidief
Foliculair lymfoom
- Hovon 110: ReBeL study: a randomized phase I/II trial of lenalidomide and rituximab with or without bendamustine in patients ≥ 18 years with relapsed follicular lymphoma. (open)
- Protocol
- Patienteninformatie
- Verpleegkundigwijzerprotocol; 8.20.3.133
- Studiemedicatie: lenalidomide (via trialbureau) en bendamustine (via medicator bij opmerkingen HOVON110, studiemedicatie)
- ARD12130 A Phase 2 study of SAR245409 in patients with relapsed or refractory mantle cell lymphoma, follicular lymphoma, or chronic lymphocytic leukemia/small lymphocytic lymphoma’ (open)
- LIFT studie: A phase Ib, multicenter, open-label study of HCD122 administered intravenously in combination with
bendamustine in patients with CD40+ follicular lymphoma who are refractory to rituximab (doorverwijzen naar VUmc)
Mantelcellymfoom
- ARD12130 A Phase 2 study of SAR245409 in patients with relapsed or refractory mantle cell lymphoma, follicular lymphoma, or chronic lymphocytic leukemia/small lymphocytic lymphoma’ (open)
Grootcellig B cel non Hodgkin lymfoom
- HOVON 80 NHL: Phase II study on the feasibility and efficacy of R-DHAP + HD-MTX, combined with autologous stem cell transplantation in patients with a recurrent aggressive B-cell lymphoma with CNS localisation (gesloten)
- HOVON 85 NHL: Phase II study on the feasibility and efficacy of consolidation with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma having achieved partial or complete remission after induction with RPECC chemotherapy. (open)
- Hovon 98: ORCHARRD. Diffuus large B-cell lymphoma. Refractair of recidief na 1e lijnsbehandeling. Inductie kuur + Ofatumumab vs Inductiekuur + Rituximab gevolgd door transplantatie voor patienten > 18 jr (open)
Anaplatisch T-cel lymoom
- Named patient programm Brentuximab: max 16 kuren om de 3 weken
Foliculair non Hodgkin Lymfoom
Folliculair Non Hodgkin lymfoom
|
|
